The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Circulating insulin‐like growth factor peptides and prostate cancer risk: A systematic review and meta‐analysis
Open accessAbstract
Insulin‐like growth factors (IGF‐I, IGF‐II) and their binding proteins (IGFBP‐1–6) play a key role in cell proliferation, differentiation and apoptosis, suggesting possible involvement in carcinogenesis. Several epidemiological studies show associations of IGFs with prostate cancer. We searched the published literature for all studies relating levels of IGFs or IGFBPs with prostate cancer. We performed random effects meta‐analysis to calculate summary odds ratios. The number of studies (prostate cancer cases) included in each meta‐analysis were 42 (7,481) IGF‐I; 10 (923) IGF‐II; 3 (485) IGFBP‐1; 5 (577) IGFBP‐2; 29 (6,541) IGFBP‐3 and 11 (3,545) IGF‐1:IGFBP‐3 ratio. The pooled odds ratios (95% confidence intervals) per standard deviation increase in peptide were: IGF‐I, OR = 1.21 (1.07, 1.36); IGF‐II, OR = 1.17 (0.93, 1.47); IGFBP‐1, OR = 1.21 (0.62, 2.33); IGFBP‐2, OR = 1.18 (0.90, 1.54); IGFBP‐3, OR = 0.88 (0.79, 0.98); IGFI:IGFBP‐3 ratio, OR = 1.10 (0.97, 1.24). For all exposures, there was substantial heterogeneity (all I 2 > 75%), partly explained by study design: the magnitude of associations was smaller in prospective vs. retrospective studies, and for IGFBP‐3, the inverse association with prostate cancer risk was seen in retrospective but not prospective studies. There was weak evidence that associations of IGF‐I and IGFBP‐3 with prostate cancer were stronger for advanced disease. Our meta‐analysis confirms that raised circulating lGF‐I is positively associated with prostate cancer risk. Associations between IGFBP‐3 and prostate cancer were inconsistent, and there was little evidence for a role of IGF‐II, IGFBP‐1 or IGFBP‐2 in prostate cancer risk. © 2008 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Operating characteristics of a rank correlation test for publication bias
Begg, C. B., & Mazumdar, M. (1994) · Biometrics · doi:10.2307/2533446 · Cited by 16,955
Assessing the quality of controlled clinical trials
Jüni, P., Altman, D. G., & Egger, M. (2001) · BMJ · doi:10.1136/bmj.323.7303.42 · Cited by 3,309
Methods for Trend Estimation from Summarized Dose-Response Data, with Applications to Meta-Analysis
Greenland, S., & Longnecker, M. P. (1992) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a116237 · Cited by 2,353
Metan: fixed- and random-effects meta-analysis
Harris, R. J., Deeks, J. J., Altman, D. G., Bradburn, M. J., Harbord, R. M., & Sterne, J. A. C. (2008) · The Stata Journal: Promoting communications on statistics and Stata · doi:10.1177/1536867x0800800102 · Cited by 1,027 · cited 1×
“We performed random and fixed effects meta-analysis to calculate summary OR estimates, using the metan command.(12) The DerSimonian and Laird model relaxes the assumption of a common treatment effect.”
Self-citationJuul, A., Scheike, T., Davidsen, M., Gyllenborg, J., & Jørgensen, T. (2002) · Circulation · doi:10.1161/01.cir.0000027563.44593.cc · Cited by 640
Cited by
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366
Obesity and Prostate Cancer: Weighing the Evidence
Allott, E. H., Masko, E. M., & Freedland, S. J. (2013) · European Urology · doi:10.1016/j.eururo.2012.11.013 · Cited by 601
Farvid, M. S., Sidahmed, E., Spence, N. D., Mante Angua, K., Rosner, B. A., & Barnett, J. B. (2021) · European Journal of Epidemiology · doi:10.1007/s10654-021-00741-9 · Cited by 447
Obesity and Cancer Risk: Recent Review and Evidence
Basen-Engquist, K., & Chang, M. (2011) · Current Oncology Reports · doi:10.1007/s11912-010-0139-7 · Cited by 439
“In meta-analyses, an increased level of IGF-I has been associated with increased risk of pre and postmenopausal breast cancers and prostate cancer [ 25 , 26].”
BackgroundUnraveling Insulin-Like Growth Factor Binding Protein-3 Actions in Human Disease
Jogie-Brahim, S., Feldman, D., & Oh, Y. (2009) · Endocrine Reviews · doi:10.1210/er.2008-0028 · Cited by 323
Dehkhoda, F., Lee, C. M. M., Medina, J., & Brooks, A. J. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00035 · Cited by 304
Richman, E. L., Kenfield, S. A., Stampfer, M. J., Paciorek, A., Carroll, P. R., & Chan, J. M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3932 · Cited by 297
Ioannidis, J. P. A. (2011) · JAMA · doi:10.1001/jama.2011.713 · Cited by 252
Garcia, J. M., Boccia, R. V., Graham, C. D., Yan, Y., Duus, E. M., Allen, S., & Friend, J. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71154-4 · Cited by 218
Milman, S., Huffman, D. M., & Barzilai, N. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.05.014 · Cited by 150
Vitale, G., Brugts, M. P., Ogliari, G., Castaldi, D., Fatti, L. M., Varewijck, A. J., Lamberts, S. W., Monti, D., Bucci, L., Cevenini, E., et al. (2012) · Aging · doi:10.18632/aging.100484 · Cited by 90
Growth and Growth Hormone Treatment in Children with Chronic Diseases
Pozzo, A. M., & Kemp, S. F. (2012) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2012.07.001 · Cited by 9
Metadata
- Authors
- Rowlands, M., Gunnell, D., Harris, R., Vatten, L. J., Holly, J. M. P., & Martin, R. M.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2009-03-16
- Volume
- 124
- Issue
- 10
- Pages
- 2416-2429
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W1987562801
- Cited by
- 251
- References
- 5
- FWCI
- 2.88
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.